Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

146661 Press Releases
DateTitleCompany
05 Dec 16 Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Kite Pharma, Inc.,
Published by
Business Wire
05 Dec 16 Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting Published by
GlobeNewswire
05 Dec 16 Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency Published by
GlobeNewswire
05 Dec 16 Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting ArQule, Inc.,
Published by
Business Wire
05 Dec 16 Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia Kite Pharma, Inc.,
Published by
Business Wire
04 Dec 16 Allscripts to extend EMR offerings in Australia Published by
GlobeNewswire
04 Dec 16 Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib) Incyte Corporation,
Published by
Business Wire
04 Dec 16 Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting Published by
GlobeNewswire
04 Dec 16 Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH Published by
GlobeNewswire
04 Dec 16 Daktari and SystemOne Announce Partnership to Bring Connected Diagnostics to Developing World Published by
GlobeNewswire
04 Dec 16 Marapharm Ventures Inc. Pays Off Mortgage on Las Vegas, Nevada Property Marapharm Ventures Inc.,
Published by
PR Newswire
04 Dec 16 New Data for Once-daily Adjunctive Zebinix® (eslicarbazepine acetate) Show Good Seizure Control and Tolerability in People With Partial Onset (Focal) Seizures Eisai,
Published by
PR Newswire
04 Dec 16 Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors Alnylam Pharmaceuticals, Inc.,
Published by
Business Wire
04 Dec 16 Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia Acetylon Pharmaceuticals, Inc.,
Published by
Business Wire
04 Dec 16 Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst® and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma Acetylon Pharmaceuticals, Inc.,
Published by
Business Wire
04 Dec 16 Dr. Samantha Stuart, DC Addresses Headache Causes and Treatment During the Holidays Published by
GlobeNewswire
04 Dec 16 Clayton Chiropractic Provides Adjustments and Techniques for Local Athletic Wellness Published by
GlobeNewswire
04 Dec 16 Nordic Nanovector: Single-dose Betalutin® Shows Promising Efficacy, Improved Duration of Response and Favourable Safety in Relapsed NHL Patients Nordic Nanovector,
Published by
Business Wire
03 Dec 16 NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors Published by
GlobeNewswire
03 Dec 16 Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma Published by
GlobeNewswire
03 Dec 16 NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors Novo Nordisk A/S,
Published by
GlobeNewswire
04 Dec 16 In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia The Children's Hospital of Philadelphia,
Published by
PR Newswire
04 Dec 16 Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Novartis International AG,
Published by
GlobeNewswire
04 Dec 16 Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Published by
GlobeNewswire
03 Dec 16 Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting Seattle Genetics, Inc.,
Published by
Business Wire
03 Dec 16 uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B uniQure,
Published by
GlobeNewswire
03 Dec 16 uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B Published by
GlobeNewswire
04 Dec 16 Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting ArQule, Inc.,
Published by
Business Wire
04 Dec 16 Celgene Corporation, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project Celgene Corporation,
Published by
Business Wire
03 Dec 16 Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study Novartis International AG,
Published by
GlobeNewswire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.